NASDAQ:NEOS - Neos Therapeutics Stock Price, Forecast & News

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

Neos Therapeutics Inc (NASDAQ:NEOS) released its quarterly earnings results on Friday, November, 8th. The company reported ($0.04) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.07. The company earned $17.54 million during the quarter. Neos Therapeutics had a negative return on equity of 2,087.24% and a negative net margin of 35.77%. View Neos Therapeutics' Earnings History.

Neos Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Neos Therapeutics.

2 equities research analysts have issued twelve-month target prices for Neos Therapeutics' stock. Their forecasts range from $3.00 to $10.00. On average, they expect Neos Therapeutics' share price to reach $6.50 in the next year. This suggests a possible upside of 327.6% from the stock's current price. View Analyst Price Targets for Neos Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neos Therapeutics.

News articles about NEOS stock have trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Neos Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Neos Therapeutics.

Some companies that are related to Neos Therapeutics include Concert Pharmaceuticals (CNCE), AMAG Pharmaceuticals (AMAG), Stemline Therapeutics (STML), Spectrum Pharmaceuticals (SPPI), Albireo Pharma (ALBO), Syros Pharmaceuticals (SYRS), OptiNose (OPTN), Wave Life Sciences (WVE), Osmotica Pharmaceuticals (OSMT), Evofem Biosciences (EVFM), Lexicon Pharmaceuticals (LXRX), Syndax Pharmaceuticals (SNDX), MannKind (MNKD), Aduro BioTech (ADRO) and Kamada (KMDA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Exelixis (EXEL), Fibrocell Science (FCSC), Progenics Pharmaceuticals (PGNX), TG Therapeutics (TGTX), Verastem (VSTM), Synergy Pharmaceuticals (SGYP), SCYNEXIS (SCYX), Amicus Therapeutics (FOLD), T2 Biosystems (TTOO) and Agile Therapeutics (AGRX).

(NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Neos Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (5.15%), Renaissance Technologies LLC (1.34%), Russell Investments Group Ltd. (1.17%), Boston Partners (0.46%), Jacobs Levy Equity Management Inc. (0.24%) and Hunter Associates Investment Management LLC (0.20%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View Institutional Ownership Trends for Neos Therapeutics.

NEOS stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Algert Global LLC, State Street Corp and Alambic Investment Management L.P.. View Insider Buying and Selling for Neos Therapeutics.

NEOS stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Renaissance Technologies LLC, Boston Partners, Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., Hunter Associates Investment Management LLC, BCS Wealth Management and Virtu Financial LLC. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View Insider Buying and Selling for Neos Therapeutics.

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEOS stock can currently be purchased for approximately $1.52.

Neos Therapeutics has a market capitalization of $75.59 million and generates $49.99 million in revenue each year. The company earns $-51,670,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe.View Additional Information About Neos Therapeutics.

The official website for Neos Therapeutics is http://www.neostx.com/.

Neos Therapeutics' mailing address is 2940 N. HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]